United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

26 Oct 2016
Change (% chg)

€-0.41 (-0.60%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for SASY.PA


Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production... (more)


Beta: 0.83
Market Cap(Mil.): €88,330.77
Shares Outstanding(Mil.): 1,289.12
Dividend: 2.93
Yield (%): 4.28


  SASY.PA Industry Sector
P/E (TTM): 21.58 36.18 36.06
EPS (TTM): 3.18 -- --
ROI: 4.96 14.41 13.90
ROE: 7.50 15.18 14.84

BRIEF-Planet.fr SA to acquire Addict Media

* Signed a memorandum of agreement with the shareholders of Société Addict Media to acquire 100% of the company

Oct 25 2016

BRIEF-Myriad RBM announces agreement with Sanofi

* Announces an agreement with Sanofi to measure predictive cardiovascular biomarkers in patients with diabetes

Oct 25 2016

Boehringer offers EU concessions over Sanofi animal health unit purchase

BRUSSELS, Oct 18 German pharmaceuticals company Boehringer Ingelheim has offered concessions in an attempt to secure EU antitrust approval for its acquisition of Sanofi's animal health unit as part of a $20 billion asset swap.

Oct 18 2016

BRIEF-Science 37 secures $31m series B funding

* Science 37 secures $31m series b funding to expand clinical trial access to anyone, anywhere, anytime

Oct 18 2016

U.S. top court will not hear fraud case over Sanofi antibiotic

The U.S. Supreme Court has declined to consider an appeal by health plans accusing French drugmaker Sanofi SA of hiding the risks of its antibiotic Ketek, which largely fell out of use in the U.S. after being linked to liver failure.

Oct 03 2016

Factbox: Biosimilar landscape cluttered with Big Pharma lawsuits

Big pharmaceutical companies are waging courtroom patent battles against each other over biosimilars, as the line blurs between companies known for their innovative medicines and those that produce cheaper biotech knock-offs.

Oct 02 2016

BRIEF-Sanofi appoints Alan Main to Executive Committee

* Sanofi appoints Alan Main to executive committee and executive vice president, consumer healthcare Source text for Eikon: Further company coverage: (Reporting By Dominique Vidalon)

Sep 30 2016

Fitch Affirms L'Oreal SA at 'F1+'

(The following statement was released by the rating agency) MILAN/LONDON, September 27 (Fitch) Fitch Ratings has affirmed L'Oreal SA's (L'Oreal) Short-Term Issuer Default Rating (IDR) and commercial paper (CP) programme at 'F1+'. The agency has also affirmed L'Oreal USA Inc's CP programme, guaranteed by L'Oreal, at 'F1+'. The ratings continue to reflect the company's strong market position and product portfolio as well as its robust geographical diversification. Also, L'Oreal continues to d

Sep 27 2016

Sanofi gets $43 million U.S. funding to spur Zika vaccine development

Sanofi SA said on Monday the U.S. Department of Health and Human Services (HHS) approved $43.18 million in funding to accelerate the development of a Zika vaccine, as efforts to prevent the infection gather momentum.

Sep 27 2016

BRIEF-U.S BARDA grants $43.2 mln to Sanofi for Zika vaccine

* The United States Biomedical Advanced Research and Development Authority (BARDA) agrees to fund the manufacture of an inactivated Zika vaccine for phase II development by Sanofi and its vaccines global business unit Sanofi Pasteur

Sep 26 2016

Earnings vs. Estimates